Nolla Health Issues First AI-Generated Acne Prescriptions in Utah

Healthcare startup Nolla Health has launched a pilot program in Utah enabling residents to obtain AI-generated prescriptions for acne treatment through its mobile application. The service allows users to scan their faces, after which an artificial intelligence system evaluates acne severity and autonomously generates prescription recommendations. Nolla Health represents the first company in the United States to utilize AI for issuing initial prescriptions, distinguishing its offering from several other healthcare firms currently piloting AI systems for medication renewals in the state. The rollout employs a tiered oversight model designed to balance automation with clinical safety. For the initial 100 patients, two physicians will manually approve each AI-generated prescription before issuance. As the pilot expands to 500 patients, oversight will shift to post-prescription reviews. Beyond that threshold, physicians will conduct monthly random audits covering at least ten percent of all prescriptions, alongside mandatory reviews of any cases involving treatment escalation or adverse reactions. Nolla Health emphasizes that the platform is intended to supplement rather than replace human clinicians by managing routine, low-acuity dermatological cases and allowing board-certified specialists to concentrate on complex or high-risk conditions. The service is priced at 4.99 dollars per month and is currently available exclusively to Utah residents aged 18 and older diagnosed with mild to moderate acne. The underlying AI model can autonomously prescribe eight distinct dermatological treatments. To maintain safety standards, the system is programmed to refer users to a qualified physician whenever it lacks the confidence to recommend a specific treatment protocol. This launch aligns with broader regulatory shifts in Utah, which recently updated its medical board guidelines to permit AI systems to renew certain prescription medications under controlled conditions. By navigating this evolving regulatory landscape, Nolla Health aims to demonstrate how algorithmic diagnostics can streamline access to affordable dermatological care while maintaining rigorous clinical safeguards. The pilot program will serve as a critical test case for the wider integration of artificial intelligence into primary and specialty care workflows across the United States.